Most of us think about cancer risk in terms of what we can see: a parent’s diagnosis, a grandmother’s mastectomy scar, the aunt everyone talks about in hushed tones. Family history is a real signal but it’s an incomplete one. A growing body of research shows that a large share of people carrying a pathogenic gene variant (genetic predisposition) linked to cancer have no obvious family history to warn them.
The gap between family history and genetic risk
Cancer risk exists on a spectrum. Most cancers are the result of a combination of age, environment, lifestyle, and chance. But for a meaningful minority of people, an inherited variant in a gene like BRCA1, BRCA2, or one of the Lynch syndrome mismatch-repair genes substantially raises lifetime risk - sometimes to well above 50%.
The clinically important fact is that family history alone misses a lot of these people. Hereditary cancer syndromes can appear on either side of a family, skip generations, or simply not have surfaced yet because relatives passed away young, from other causes, or before reaching the age when a cancer would typically appear. This is one reason clinical guidelines have moved toward broader, gene-panel based testing rather than testing based on family history checklists alone.
Why this matters for prevention, not just diagnosis
A pathogenic variant is not a diagnosis. It’s information - a data point that changes what surveillance or risk-reduction options might be worth discussing with your doctor or a specialist. For BRCA1/2 carriers specifically, published research on risk-reducing strategies (enhanced screening, medication, and in some cases risk-reducing surgery) shows these interventions can drastically reduce lifetime cancer risk. The value of finding out isn’t the result itself - it’s the years of lead time it can create to act on that information with a clinician’s guidance.
Roughly 1 in 20 people carry an inherited health risk that could change how they and their doctor approach preventive care. That’s a far bigger group than “people with a strong family history.” Yet under current international testing criteria, a 2026 Australian study found that nearly three-quarters of people carrying a hereditary cancer variant would not have qualified for government-funded genetic testing based on family history alone.
What proactive screening looks for
Modern preventative genetic screening typically looks only for pathogenic and likely pathogenic variants in genes where a positive finding would actually change medical management - not variants of unknown significance that create anxiety without a clear next step. This is a deliberate design choice: the goal is actionable information, not noise.
If a result comes back positive, genetic counselling is a critical part of the process. It helps translate a lab report into a personalised risk picture and a realistic plan. It’s also the moment to have an honest conversation about what a result might mean beyond your own health including, in some places, for insurance (more on that in a separate piece).
While a positive result is incredibly powerful information for some it is most certainly cannot clear other risks related to other environmental, familial or yet-to-be discovered genetic risks. We always recommend seeking expert advice if you have symptoms and establishing the relevant care team for you based on your specific scenario and needs.
The bottom line
Cancer risk isn’t just about what happened to your relatives. It’s about what’s written into your own genome, and whether you and your doctor have the chance to act on that information before, rather than after, a diagnosis. Family history is a useful conversation starter, it was never meant to be the whole conversation.
This article is general information, not medical advice. A genetic test result is not a diagnosis, and decisions about testing or risk management should be made with a qualified healthcare provider or genetic counsellor.
References
- Greenberg S, Buys SS, Edwards SL, Espinel W, Fraser A, Gammon A, Hafen B, Herget KA, Kohlmann W, Roundy C, Sweeney C. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. Cancer Med. 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825998/
- Bucheit L, Johansen Taber K, Ready K. Validation of a digital identification tool for individuals at risk for hereditary cancer syndromes. Hered Cancer Clin Pract. 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330430/
- Ekstein T, Aguilar S, Russell E (2026) Genetic findings and health care utilization among individuals undergoing population genomic screening for actionable hereditary disorders Genetics in Medicine. https://www.gimjournal.org/article/S1098-3600(26)00923-8/fulltext
- Lacaze, P., Tiller, J., Brotchie, A. et al. Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot. Nature Health (2026) https://doi.org/10.1038/s44360-025-00020-x
Support groups
- Australia: Inherited Cancers Australia (formerly Pink Hope) — national charity supporting families with inherited cancer risk, including online and in-person peer support and a specialist nurse service. https://www.inheritedcancers.org.au/
- United States: FORCE — Facing Our Risk of Cancer Empowered — support and community for people with hereditary cancer mutations, including virtual peer support groups. https://www.facingourrisk.org/
